The Lancet Diabetes and Endocrinology

Top Research Topics at The Lancet Diabetes & Endocrinology?

The Lancet Diabetes & Endocrinology facilitates discussions on Internal medicine, Diabetes mellitus, Type 2 diabetes, Endocrinology and Intensive care medicine. The Lancet Diabetes & Endocrinology is focused mainly on Internal medicine, particularly Randomized controlled trial. Adverse effect and Clinical trial are some topics wherein Randomized controlled trial research discussed in it have an impact.

The research on Diabetes mellitus featured in the journal combines topics in other fields like Insulin, Obesity, Disease and Gerontology. The works on Obesity deal in particular with Overweight. In The Lancet Diabetes & Endocrinology, Metformin and Cohort study are investigated in conjunction with one another to address concerns in Type 2 diabetes research.

• Internal medicine (34.57%)
• Diabetes mellitus (33.85%)
• Type 2 diabetes (19.89%)

What are the most cited papers published in the journal?

• Vitamin D status and ill health: a systematic review (721 citations)
• Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables (711 citations)
• Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome (577 citations)

Research areas of the most cited articles at The Lancet Diabetes & Endocrinology:

The most cited articles facilitate discussions on Internal medicine, Diabetes mellitus, Type 2 diabetes, Endocrinology and Surgery. The journal papers dive deep in exploring the relationship between the study of Internal medicine and Placebo. While the most cited publications focused on Diabetes mellitus, they were also able to explore topics like Obesity, Disease and Gerontology.

What topics the last edition of the journal is best known for?

• Internal medicine
• Disease
• Diabetes mellitus

The previous edition focused in particular on these issues:

The journal investigates studies in Internal medicine, Diabetes mellitus, Type 2 diabetes, Coronavirus disease 2019 (COVID-19) and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Lancet Diabetes & Endocrinology explores topics in Internal medicine which can be helpful for research in disciplines like Placebo and Cardiology. While Placebo is the focus of The Lancet Diabetes & Endocrinology, it also provided insights into the studies of Randomized controlled trial and Clinical trial.

The majority of Diabetes mellitus studies in it are focused on the subject of Type 1 diabetes. The Type 2 diabetes research presented in The Lancet Diabetes & Endocrinology explores the relationship between Kidney disease and the closely related topic of Dapagliflozin. The studies in Cohort study featured incorporate elements of Odds ratio, Pregnancy, Pediatrics and Risk factor.

The most cited articles from the last journal are:

• Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. (72 citations)
• Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial (50 citations)
• Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. (48 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in The Lancet Diabetes & Endocrinology (based on the number of publications) are:

• Naveed Sattar (52 papers) published 4 papers at the last edition the same number as at the previous edition,
• David Preiss (28 papers) absent at the last edition,
• Hiddo J.L. Heerspink (27 papers) published 4 papers at the last edition the same number as at the previous edition,
• Fiona Mitchell (26 papers) published 1 paper at the last edition, 7 less than at the previous edition,
• Kamlesh Khunti (26 papers) published 4 papers at the last edition, 3 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in The Lancet Diabetes & Endocrinology (based on the number of publications) are:

• Harvard University (100 papers) published 9 papers at the last edition, 1 more than at the previous edition,
• University College London (66 papers) published 4 papers at the last edition, 1 less than at the previous edition,
• University of Cambridge (62 papers) published 5 papers at the last edition, 8 less than at the previous edition,
• National Institutes of Health (61 papers) published 6 papers at the last edition, 1 less than at the previous edition,
• Imperial College London (60 papers) published 7 papers at the last edition, 2 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 14.67% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 33.59% were posted by at least one author from the top 10 institutions publishing in the journal. Another 10.94% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 17.19% of all publications and 38.28% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Future Research Directions in The Lancet Diabetes & Endocrinology

The ongoing medical research developments call for newer ventures and deeper studies into specific topics. The Lancet Diabetes & Endocrinology, being a leader in publishing about internal medicine and issues related to diabetes, can explore a multitude of dimensions in upcoming research publications.

One potential area worthy of consideration is the study of the impacts of lifestyle choices and environmental factors on the prevalence of diabetes, particularly in younger populations. Such studies could contribute significantly in steering healthcare policies and preventive measures, globally.

With the rise of remote learning and digitalization across various sectors, there is also an emerging need to understand the impact of technology in the field of medicine and healthcare. Specifically, researching the effectiveness and efficiencies of online nursing programs, such as those found in the best online nursing programs in Texas, may provide interesting and useful insights in the times to come.

Investigating the evolution of treatments, the efficacy of new drugs, and the progression in surgical techniques for diabetes treatment can provide valuable insights for medical practitioners. Research on the implications of the pandemic on diabetic patients and its management through telehealth could also be a timely investigation.

Finally, analyzing the applications and implications of Artificial intelligence in diagnosing and managing diabetes might pave the way for advanced methodologies and tools in future medical practices.

These future research directions could offer a myriad of opportunities for innovation in medical research, subsequently fostering progress in the healthcare sector, and improving patient outcomes substantially.